Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s traded shares stood at 0.59 million during the latest session, with the company’s beta value hitting 0.47. At the last check today, the stock’s price was $1.37, to imply a decrease of -3.52% or -$0.05 in intraday trading. The GLMD share’s 52-week high remains $23.80, putting it -1637.23% down since that peak but still an impressive 11.68% since price per share fell to its 52-week low of $1.21. The company has a valuation of $3.10M, with an average of 89960.0 shares in intraday trading volume over the past 10 days and average of 864.15K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Galmed Pharmaceuticals Ltd (GLMD), translating to a mean rating of 1.00. Of 7 analyst(s) looking at the stock, 0 analyst(s) give GLMD a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) trade information
After registering a -3.52% downside in the latest session, Galmed Pharmaceuticals Ltd (GLMD) has traded red over the past five days. The 5-day price performance for the stock is -6.16%, and -22.62% over 30 days. With these gigs, the year-to-date price performance is -57.05%. Short interest in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) saw shorts transact 48498.0 shares and set a 1.67 days time to cover.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 45.91% for the past 5-year period. While 2025 is set for a 64.49% return in earnings, projections for the next 5 years are at 62.35% annually.
GLMD Dividends
Galmed Pharmaceuticals Ltd has its next earnings report out on 2024-Apr-03. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s Major holders
Galmed Pharmaceuticals Ltd insiders hold 1.26% of total outstanding shares, with institutional holders owning 2.06% of the shares at 2.08% float percentage. In total, 2.06% institutions holds shares in the company.
Going by data provided on Dec 31, 2024 , Delaware Group Equity Funds IV-Macquarie Healthcare Fund holds roughly 1.7 shares. This is just over 0.08% of the total shares, with a market valuation of $2415.0
